Venous thromboembolism in patients with inflammatory bowel disease: Focus on prevention and treatment

World Journal of Gastroenterology

Volumn 20, Issue 12, 2014, Pages 3173-3179

  Papa, Alfredo ^a   Gerardi, Viviana ^a   Marzo, Manuela ^a   Felice, Carla ^a   Rapaccini, Gian Lodovico ^a   Gasbarrini, Antonio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Anticoagulants; Inflammatory bowel disease; Low molecular weight heparin; Thromboembolic prophylaxis; Unfractionated heparin; Venous throm boembolism

Indexed keywords

AZATHIOPRINE; HEPARIN; INFLIXIMAB; LOW MOLECULAR WEIGHT HEPARIN; MERCAPTOPURINE; ANTICOAGULANT AGENT;

ARTICLE; COLON RESECTION; COMPUTER ASSISTED TOMOGRAPHY; DEHYDRATION; FAMILIAL COLON POLYPOSIS; GENE MUTATION; HOSPITALIZATION; HUMAN; HYPERHOMOCYSTEINEMIA; INDWELLING CATHETER; INFECTION; INFLAMMATORY BOWEL DISEASE; LUNG EMBOLISM; MORBIDITY; MORTALITY; OBESITY; ORAL CONTRACEPTIVE USE; RISK FACTOR; SMOKING; VENOUS THROMBOEMBOLISM; COMPLICATION; INCIDENCE; PATIENT COMPLIANCE; PATIENT SAFETY; TREATMENT OUTCOME;

ANTICOAGULANTS; HUMANS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; PATIENT COMPLIANCE; PATIENT SAFETY; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84896945284     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i12.3173     Document Type: Article

References (48)

1. Yuhara H, Steinmaus C, Corley D, Koike J, Igarashi M, Suzuki T, Mine T. Meta-analysis: the risk of venous thrombo-embolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 37: 953-962 [PMID: 23550660 DOI: 10.1111/apt.12294]
2. Papa A, Scaldaferri F, Danese S, Guglielmo S, Roberto I, Bonizzi M, Mocci G, Felice C, Ricci C, Andrisani G, Fedeli G, Gasbarrini G, Gasbarrini A. Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects. Dig Dis 2008; 26: 149-155 [PMID: 18431065 DOI: 10.1159/000116773]
3. Miehsler W, Reinisch W, Valic E, Osterode W, Tillinger W, Feichtenschlager T, Grisar J, Machold K, Scholz S, Vogelsang H, Novacek G. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 2004; 53: 542-548 [PMID: 15016749 DOI: 10.1136/ gut.2003.025411]
4. Kappelman MD, Horvath-Puho E, Sandler RS, Rubin DT, Ullman TA, Pedersen L, Baron JA, Sørensen HT. Throm-boembolic risk among Danish children and adults with in-flammatory bowel diseases: a population-based nationwide study. Gut 2011; 60: 937-943 [PMID: 21339206 DOI: 10.1136/ gut.2010.228585]
5. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010; 375: 657-663 [PMID: 20149425 DOI: 10.1016/S0140-6736(09)61963-2]
6. Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004; 99: 97-101 [PMID: 14687149 DOI: 10.1046/ j.1572-0241.2003.04026.x]
7. Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001; 85: 430-434 [PMID: 11307809]
8. Nguyen GC, Sam J. Rising prevalence of venous throm-boembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroen-terol 2008; 103: 2272-2280 [PMID: 18684186 DOI: 10.1111/ j.1572-0241.2008.02052.x]
9. Talbot RW, Heppell J, Dozois RR, Beart RW. Vascular complications of inflammatory bowel disease. Mayo Clin Proc 1986; 61: 140-145 [PMID: 3080643 DOI: 10.1016/ S0025-6196(12)65200-8]
10. Murthy SK, Nguyen GC. Venous thromboembolism in inflammatory bowel disease: an epidemiological review. Am J Gastroenterol 2011; 106: 713-718 [PMID: 21407182 DOI: 10.1038/ajg.2011.53]
11. Danese S, Papa A, Saibeni S, Repici A, Malesci A, Vecchi M. Inflammation and coagulation in inflammatory bowel disease: The clot thickens. Am J Gastroenterol 2007; 102: 174-186 [PMID: 17100967 DOI: 10.1111/j.1572-0241.2006.00943.x]
12. Huerta C, Johansson S, Wallander MA, García Rodríguez LA. Risk factors and short-term mortality of venous throm-boembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 2007; 167: 935-943 [PMID: 17502535 DOI: 10.1001/archinte.167.9.935]
13. Nguyen GC, Boudreau H, Harris ML, Maxwell CV. Outcomes of obstetric hospitalizations among women with inflammatory bowel disease in the United States. Clin Gas-troenterol Hepatol 2009; 7: 329-334 [PMID: 19027089 DOI: 10.1016/j.cgh.2008.10.022]
14. Johns DR. Cerebrovascular complications of inflammatory bowelisease. Am J Gastroenterol 1991; 86: 367-370 [PMID: 1998321]
15. Landman C, Nahon S, Cosnes J, Bouhnik Y, Brixi-Benman-sour H, Bouguen G, Colombel JF, Savoye G, Coffn B, Abitbol V, Filippi J, Laharie D, Moreau J, Veyrac M, Allez M, Marteau P. Portomesenteric vein thrombosis in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 582-589 [PMID: 23385240 DOI: 10.1097/MIB.0b013e31827eea5f]
16. Schneiderman JH, Sharpe JA, Sutton DM. Cerebral and retinal vascular complications of inflammatory bowel disease. Ann Neurol 1979; 5: 331-337 [PMID: 443768 DOI: 10.1002/ ana.410050405]
17. Hatoum OA, Spinelli KS, Abu-Hajir M, Attila T, Franco J, Otterson MF, Telford GL, Binion DG. Mesenteric venous thrombosis in inflammatory bowel disease. J Clin Gas-troenterol 2005; 39: 27-31 [PMID: 15599206 DOI: 10.1111/ j.1572-0241.2003.08524.x]
18. Papay P, Miehsler W, Tilg H, Petritsch W, Reinisch W, Mayer A, Haas T, Kaser A, Feichtenschlager T, Fuchssteiner H, Knoflach P, Vogelsang H, Platzer R, Tillinger W, Jaritz B, Schmid A, Blaha B, Dejaco C, Sobala A, Weltermann A, Eichinger S, Novacek G. Clinical presentation of venous thromboembolism in inflammatory bowel disease. J Crohns Colitis 2013; 7: 723-729 [PMID: 23127785 DOI: 10.1016/ j.crohns.2012.10.008]
19. Papa A, Danese S, Grillo A, Gasbarrini G, Gasbarrini A. Review article: inherited thrombophilia in inflammatory bowel disease. Am J Gastroenterol 2003; 98: 1247-1251 [PMID: 12818264 DOI: 10.1111/j.1572-0241.2003.07491.x]
20. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005; 131: 417-430 [PMID: 16281932 DOI: 10.1111/j.1365-2141.2005.05753.x]
21. Levi M, van der Poll T, Büller HR. Bidirectional relation between inflammation and coagulation. Circulation 2004; 109: 2698-2704 [PMID: 15184294 DOI: 10.1161/01]
22. Oldenburg B, Van Tuyl BA, van der Griend R, Fijnheer R, van Berge Henegouwen GP. Risk factors for thromboembol-ic complications in inflammatory bowel disease: the role of hyperhomocysteinaemia. Dig Dis Sci 2005; 50: 235-240 [PMID: 15745078 DOI: 10.1007/s10620-005-1588-y]
23. Carty E, MacEy M, Rampton DS. Inhibition of platelet activation by 5-aminosalicylic acid in inflammatory bowel disease. Aliment Pharmacol Ther 2000; 14: 1169-1179 [PMID: 10971234 DOI: 10.1046/j.1365-2036.2000.00824.x]
24. Thomas G, Skrinska VA, Lucas FV. The influence of glu-tathione and other thiols on human platelet aggregation. Thromb Res 1986; 44: 859-866 [PMID: 3099423 DOI: 10.1016/0 049-3848(86)90031-9]
25. Hommes DW, van Dullemen HM, Levi M, van der Ende A, Woody J, Tytgat GN, van Deventer SJ. Beneficial effect of treatment with a monoclonal anti-tumor necrosis factor-alpha antibody on markers of coagulation and fbrinolysis in patients with active Crohn's disease. Haemostasis 1997; 27: 269-277 [PMID: 9731107 DOI: 10.1159/000217467]
26. Danese S, Sans M, Scaldaferri F, Sgambato A, Rutella S, Cit-tadini A, Piqué JM, Panes J, Katz JA, Gasbarrini A, Fiocchi C. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infiximab in Crohn's disease. J Immunol 2006; 176: 2617-2624 [PMID: 16456024]
27. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Balekian AA, Klein RC, Le H, Schulman S, Murad MH. Prevention of VTE in nonsurgical patients: An-tithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e195S-e226S [PMID: 22315261 DOI: 10.1378/chest.11-2296]
28. Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, Guslandi M, Oldenburg B, Dotan I, Marteau P, Ardizzone A, Baumgart DC, D'Haens G, Gionch-etti P, Portela F, Vucelic B, Söderholm J, Escher J, Koletzko S, Kolho KL, Lukas M, Mottet C, Tilg H, Vermeire S, Carbonnel F, Cole A, Novacek G, Reinshagen M, Tsianos E, Herrlinger K, Oldenburg B, Bouhnik Y, Kiesslich R, Stange E, Travis S, Lindsay J. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis 2010; 4: 63-101 [PMID: 21122490 DOI: 10.1016/j.crohns.2009.09.009]
29. Van Assche G, Dignass A, Bokemeyer B, Danese S, Gionch-etti P, Moser G, Beaugerie L, Gomollón F, Häuser W, Her-rlinger K, Oldenburg B, Panes J, Portela F, Rogler G, Stein J, Tilg H, Travis S, Lindsay JO. Second European evidence-based consensus on the diagnosis and management of ulcer-ative colitis part 3: special situations. J Crohns Colitis 2013; 7: 1-33 [PMID: 23040453 DOI: 10.1016/j.crohns.2012.09.005]
30. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105: 501-523; quiz 524 [PMID: 20068560 DOI: 10.1038/ajg.2009.727]
31. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, Mitton S, Orchard T, Rutter M, Younge L, Lees C, Ho GT, Satsangi J, Bloom S. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60: 571-607 [PMID: 21464096 DOI: 10.1136/gut.2010.224154]
32. Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 2007; 146: 278-288 [PMID: 17310052 DOI: 10.7326/0003-4819-146-4-200702200-00007]
33. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874-879 [PMID: 15289368]
34. Scarpa M, Pilon F, Pengo V, Romanato G, Ruffolo C, Erroi F, Elisa B, Frego M, Ossi E, Manzato E, Angriman I. Deep venous thrombosis after surgery for inflammatory bowel disease: is standard dose low molecular weight heparin prophylaxis enough? World J Surg 2010; 34: 1629-1636 [PMID: 20177681 DOI: 10.1007/s00268-010-0490-8]
35. O'Connor OJ, Cahill RA, Kirwan WO, Redmond HP. The incidence of postoperative venous thrombosis among patients with ulcerative colitis. Ir J Med Sci 2005; 174: 20-22 [PMID: 16285333 DOI: 10.1007/BF03169142]
36. Ra G, Thanabalan R, Ratneswaran S, Nguyen GC. Predictors and safety of venous thromboembolism prophylaxis among hospitalized inflammatory bowel disease patients. J Crohns Colitis 2013; 7: e479-e485 [PMID: 23537817 DOI: 10.1016/ j.crohns.2013.03.002]
37. Tinsley A, Naymagon S, Enomoto LM, Hollenbeak CS, Sands BE, Ullman TA. Rates of pharmacologic venous thromboembolism prophylaxis in hospitalized patients with active ulcerative colitis: results from a tertiary care center. J Crohns Colitis 2013; 7: e635-e640 [PMID: 23706933 DOI: 10.1016/j.crohns.2013.05.002]
38. Sam JJ, Bernstein CN, Razik R, Thanabalan R, Nguyen GC. Physicians' perceptions of risks and practices in venous thromboembolism prophylaxis in inflammatory bowel disease. Dig Dis Sci 2013; 58: 46-52 [PMID: 23053902 DOI: 10.1007/s10620-012-2435-6]
39. Tinsley A, Naymagon S, Trindade AJ, Sachar DB, Sands BE, Ullman TA. A survey of current practice of venous thromboembolism prophylaxis in hospitalized inflammatory bowel disease patients in the United States. J Clin Gastroenterol 2013; 47: e1-e6 [PMID: 22476043 DOI: 10.1097/ MCG.0b013e31824c0dea]
40. Papa A, Danese S, Gasbarrini A, Gasbarrini G. Review article: potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease. Aliment Pharmacol Ther 2000; 14: 1403-1409 [PMID: 11069310]
41. Shen J, Ran ZH, Tong JL, Xiao SD. Meta-analysis: The utility and safety of heparin in the treatment of active ulcerative colitis. Aliment Pharmacol Ther 2007; 26: 653-663 [PMID: 17697199 DOI: 10.1111/j.1365-2036.2007.03418.x]
42. Panés J, Esteve M, Cabré E, Hinojosa J, Andreu M, Sans M, Fernandez-Bañares F, Feu F, Gassull MA, Piqué JM. Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis. Gastroenterology 2000; 119: 903-908 [PMID: 11040177]
43. Zitomersky NL, Verhave M, Trenor CC. Thrombosis and inflammatory bowel disease: a call for improved awareness and prevention. Infamm Bowel Dis 2011; 17: 458-470 [PMID: 20848518 DOI: 10.1002/ibd.21334]
44. Wallaert JB, De Martino RR, Marsicovetere PS, Goodney PP, Finlayson SR, Murray JJ, Holubar SD. Venous throm-boembolism after surgery for inflammatory bowel disease: are there modifiable risk factors? Data from ACS NSQIP. Dis Colon Rectum 2012; 55: 1138-1144 [PMID: 23044674 DOI: 10.1097/DCR.0b013e3182698f60]
45. Novacek G, Weltermann A, Sobala A, Tilg H, Petritsch W, Reinisch W, Mayer A, Haas T, Kaser A, Feichtenschlager T, Fuchssteiner H, Knoflach P, Vogelsang H, Miehsler W, Platzer R, Tillinger W, Jaritz B, Schmid A, Blaha B, Dejaco C, Eichinger S. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology 2010; 139: 779-787, 787.e1 [PMID: 20546736 DOI: 10.1053/ j.gastro.2010.05.026]
46. Nguyen GC, Bernstein CN. Duration of anticoagulation for the management of venous thromboembolism in inflammatory bowel disease: a decision analysis. Am J Gastroen-terol 2013; 108: 1486-1495 [PMID: 23857476 DOI: 10.1038/ ajg.2013.220]
47. Tabibian JH, Streiff MB. Inflammatory bowel disease-associated thromboembolism: a systematic review of outcomes with anticoagulation versus catheter-directed thrombolysis. Infamm Bowel Dis 2012; 18: 161-171 [PMID: 21805543 DOI: 10.1002/ibd.21307]
48. Lopez PR, Stewart DW, Smalligan RD. Recurrent deep vein thrombosis despite warfarin therapy in a patient with Crohn's disease. Postgrad Med 2010; 122: 181-184 [PMID: 20463427 DOI: 10.3810/pgm.2010.05.2155]